Overview
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are:
- What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment?
- How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.
Description
The objective of this observational study is to assess the effectiveness and long-term clinical outcomes of various neoadjuvant immunotherapies in patients with non-small cell lung cancer (NSCLC), using the real-world data. The primary inquiries it seeks to address include:
- What is the optimal strategy for utilizing immune checkpoint inhibitors as neoadjuvant therapy?
- How can we identify specific patient subgroups that derive the greatest benefit from neoadjuvant immunotherapy? Participants will undergo neoadjuvant immunotherapy, and the study will meticulously analyze real-world data to provide insights into these pivotal questions, contributing to the refinement of treatment strategies and patient care in NSCLC management.
Eligibility
Inclusion Criteria:
- Histological diagnosis of non-small cell lung cancer (Stage I-IV, International Association for the Study of Lung Cancer staging eighth edition)
- Patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment;
- No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment;
- Eastern Cooperative Oncology Group (ECOG) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery;
- At least one measurable lesion (RECIST v1.1).
Exclusion Criteria:
- Patients included in unblinded clinical trials or anti-tumor drug intervention.
- Radiotherapy or systemic therapy were used for NSCLC patients before the surgery.